多能干细胞来源的视网膜色素上皮细胞在治疗年龄相关性黄斑变性中的挑战与前景  

Challenges and Prospects of Pluripotent Stem Cell-Derived Retinal Pigment Epithelium in Age-Related Macular Degeneration Therapy

作　　者：张明琦 刘晓丽 赵艳 王卓实[1] ZHANG Mingqi;LIU Xiaoli;ZHAO Yan;WANG Zhuoshi(Liaoning Heshi Medical College,Shenyang 110125,China)

机构地区：[1]辽宁何氏医学院,沈阳110125

出　　处：《中国医药指南》2024年第14期72-75,共4页Guide of China Medicine

基　　金：沈阳市中青年科技创新人才支持计划(RC210438);沈阳市科学技术计划(No.20-301-4-00)。

摘　　要：多能干细胞(PSC)来源的视网膜色素上皮细胞(RPE)已成为治疗年龄相关性黄斑变性(AMD)潜在的治疗方法之一。然而,PSC诱导分化的RPE存在一些潜在的安全性问题,如未分化PSC或基因组和表观基因组异常等细胞致瘤的危险因素,因此成为研究者们重点关注的问题。本文将重点综述PSC来源的RPE细胞的纯化方法、体外检测未分化PSC残留的方法以及基因组和表观基因组异常对RPE细胞的影响。Pluripotent stem cell(PSC)derived retinal pigment epithelium(RPE)has emerged as a potential therapeutic approach for age-related macular degeneration(AMD)treatment.However,the use of PSC-induced RPE raises important safety concerns,such as the presence of undifferentiated PSCs or genomic and epigenomic abnormalities associated with tumorigenic risks.Therefore,these issues have become a central focus for researchers.This review highlights the purification methods of PSC-derived RPE cells,techniques for detecting residual undifferentiated PSCs in vitro,and the impact of genomic and epigenomic abnormalities on RPE cells.

关 键 词：视网膜色素上皮细胞 多能干细胞 检测未分化细胞 基因组和表观基因组异常 

分 类 号：R774.5[医药卫生—眼科]